TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21997672

Group type: EXPERIMENTAL
Intervention: Femoral neck puncture technique
Number of subjects: 59

Group type: COMPARATOR
Intervention: Femoral head puncture technique
Number of subjects: 59
Study: 20175705

Group type: EXPERIMENTAL
Intervention: recombinant FSH (rFSH)
Number of subjects: 49

Group type: COMPARATOR
Intervention: lyophilised urinary hMG (HP‐hMG)
Number of subjects: 49
Study: 18317375

Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise (20% 1RM)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Low-intensity resistance exercise with blood flow restriction (REFR)
Number of subjects: 6
Study: 16680252

Group type: EXPERIMENTAL
Intervention: tranexamic acid (10 mg x kg(‐1))
Number of subjects: 105
Study: 15732235

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/day
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 10862158

Group type: EXPERIMENTAL
Intervention: rhDNase (2.5 mg qd)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: rhDNase
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 9322569

Group type: EXPERIMENTAL
Intervention: Oral thiamine (10 mg/d)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 8383578

Group type: EXPERIMENTAL
Intervention: Aspirin at 1 g/day
Number of subjects: 303

Group type: COMPARATOR
Intervention: Control (no aspirin)
Number of subjects: 303
Study: 3956939

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (during the experiment)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (not smoking)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 37
Study: 3046351

Group type: EXPERIMENTAL
Intervention: Silver-impregnated cuff
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control (without cuff)
Number of subjects: 234
Study: 30616698

Group type: EXPERIMENTAL
Intervention: Healthy Activity Program (HAP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Counselling for Alcohol Problems (CAP)
Number of subjects: 50
Study: 29376886

Group type: EXPERIMENTAL
Intervention: scalp acupuncture + low frequency rTMS + routine rehabilitation treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: scalp acupuncture + routine rehabilitation treatment
Number of subjects: 28
Study: 26803187

Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT) and Concomitant Chemotherapy (CCT)
Number of subjects: 117
Study: 25693890

Group type: EXPERIMENTAL
Intervention: Glucose (25 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspartame-sweetened control drink
Number of subjects: 0
Study: 23284151

Group type: EXPERIMENTAL
Intervention: Successful smoking cessation
Number of subjects: 491

Group type: COMPARATOR
Intervention: Relapse to smoking
Number of subjects: 491
Study: 20533761

Group type: EXPERIMENTAL
Intervention: Loratadine/montelukast (10 mg/10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18781853

Group type: EXPERIMENTAL
Intervention: CYP2C19*2 carriers
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: CYP2C19*2 genotype and nongenetic risk factors (age >65 years, Type 2 diabetes mellitus, decreased left ventricular function, renal failure, acute coronary syndrome)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Nongenetic factors
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: CYP2C19*2 genotype
Number of subjects: 237
Study: 16755268

Group type: EXPERIMENTAL
Intervention: 2 measurements of biomarkers
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: 1 measurement of biomarkers
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: 3 or 4 measures of biomarkers
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: 1 measurement of ascorbic acid and malondialdehyde
Number of subjects: 206
Study: 15307693

Group type: EXPERIMENTAL
Intervention: Yiqi Yangyin Huoxue Tongfu (YYHT) principle
Number of subjects: 40

Group type: COMPARATOR
Intervention: rosiglitazone (Control)
Number of subjects: 40
Study: 11297959

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg daily elemental zinc)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study: 9052564

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 100
Study: 7509243

Group type: EXPERIMENTAL
Intervention: Terazosin (1 to 10 mg once daily for 24 weeks)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (once daily for 24 weeks)
Number of subjects: 160
Study: 3080693

Group type: EXPERIMENTAL
Intervention: TRH 150 mg subcutaneous injection
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: TRH 500 mg IV infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31898118

Group type: EXPERIMENTAL
Intervention: HRA + coaching
Number of subjects: 411

Group type: COMPARATOR
Intervention: HRA‐alone
Number of subjects: 411
Study: 29987899

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (MS)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (MS) plus avanafil
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Avanafil
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: l-carnitine
Number of subjects: 217

Group type: COMPARATOR
Intervention: No treatment (Control Group E)
Number of subjects: 217
Study: 27133819

Group type: EXPERIMENTAL
Intervention: ATRA and chemotherapy (CHT)
Number of subjects: 184

Group type: COMPARATOR
Intervention: ATRA and arsenic trioxide (ATO)
Number of subjects: 184

Group type: COMPARATOR
Intervention: FLT3-ITD positive patients receiving ATRA-CHT
Number of subjects: 184

Group type: COMPARATOR
Intervention: FLT3-ITD mutations in patients receiving ATRA-ATO
Number of subjects: 184
Study: 24497338

Group type: EXPERIMENTAL
Intervention: Catheter Ablation (CA)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Antiarrhythmic Drugs (AAD)
Number of subjects: 201
Study: 22064737

Group type: COMPARATOR
Intervention: Avilamycin (44 mg/kg)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Rosemary essential oil (100 mg/kg)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Oregano essential oil (100 mg/kg)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Rosemary and oregano essential oils (50 mg each/kg)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Commercial blend of essential oils (1,000 mg/kg)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Control diet (CON)
Number of subjects: 750
Study: 20472590

Group type: EXPERIMENTAL
Intervention: Early season skim milk
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Late season skim milk
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ultrafiltrated MPC 85 skim milk
Number of subjects: 16

Group type: COMPARATOR
Intervention: Soy control
Number of subjects: 16
Study: 18822453

Group type: EXPERIMENTAL
Intervention: 1997 Partin tables
Number of subjects: 271

Group type: COMPARATOR
Intervention: 2001 Partin tables
Number of subjects: 271
Study: 15904499

Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation programme
Number of subjects: 1997

Group type: COMPARATOR
Intervention: Hospital-based cardiac rehabilitation programme
Number of subjects: 1997
Study: 12528578

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF) in high support sitting
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF) in left side‐lying
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Staged basal expansion (SBE) in high support sitting
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Staged basal expansion (SBE) in left side‐lying
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF) and SBE in high support sitting and left side‐lying
Number of subjects: 7
Study: 11218894

Group type: EXPERIMENTAL
Intervention: Group 1: 10% glucose 500 ml + danshen compound 14 ml + low molecular weight dextran 500 ml i.v.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Group 2: 10% glucose 500 ml + danshen compound 14 ml + low molecular weight dextran 500 ml i.v. + 25% magnesium sulfate 20 ml in 5% glucose 500 ml i.v.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Group 3: no treatment given.
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group: 12 normal term delivery women.
Number of subjects: 39
Study: 9352146

Group type: EXPERIMENTAL
Intervention: Nurse-practitioner using a computer decision-support system (CDSS) in group A (therapeutic range 2-3)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Trainee doctors (clinicians) in group A (therapeutic range 2-3)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Nurse-practitioner using a computer decision-support system (CDSS) in group B (therapeutic range 3-4.5)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Trainee doctors (clinicians) in group B (therapeutic range 3-4.5)
Number of subjects: 177
Study: 8458057

Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg once daily
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo 2.5 mg once daily
Number of subjects: 58
Study: 2957124

Group type: EXPERIMENTAL
Intervention: Upper arm injection of 20 micrograms LHRH
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lower abdominal wall injection of 20 micrograms LHRH
Number of subjects: 9

Group type: COMPARATOR
Intervention: Order of injections (upper arm first vs lower abdominal wall first)
Number of subjects: 9
Study: 31513453

Group type: EXPERIMENTAL
Intervention: Letrozole (Femar®/Femara®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exemestane (Aromasin®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 28577666

Group type: EXPERIMENTAL
Intervention: 6-month dual antiplatelet therapy (DAPT) after Resolute Integrity stent implantation
Number of subjects: 1100

Group type: COMPARATOR
Intervention: 12-month dual antiplatelet therapy (DAPT)
Number of subjects: 1100
Study: 24761812

Group type: EXPERIMENTAL
Intervention: Culturally sensitive health education intervention for Latina mothers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 23801158

Group type: EXPERIMENTAL
Intervention: Oncotype DX testing
Number of subjects: 951
Study: 21807330

Group type: EXPERIMENTAL
Intervention: Water-based gymnastic exercises (CHFw)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Land-based training (CHFl)
Number of subjects: 48
Study: 19027814

Group type: EXPERIMENTAL
Intervention: Trilucent breast implants (TBI)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Reference group (REBI)
Number of subjects: 47
Study: 16436822

Group type: EXPERIMENTAL
Intervention: Functional MR imaging during deception (lie-only condition)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Functional MR imaging during truth telling (truth-only condition)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Polygraph examination for deceptive subjects
Number of subjects: 11

Group type: COMPARATOR
Intervention: Polygraph examination for truthful subjects
Number of subjects: 11
Study: 15522471

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 7599

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7599
Study: 11243557

Group type: EXPERIMENTAL
Intervention: New goniometric technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional forearm passive range‐of‐motion goniometry
Number of subjects: 30
Study: 9476456

Group type: EXPERIMENTAL
Intervention: Full-term small-for-gestational age (SGA) neonates
Number of subjects: 25

Group type: COMPARATOR
Intervention: Term appropriate-for-gestational age (AGA) neonates
Number of subjects: 25
Study: 8200567

Group type: EXPERIMENTAL
Intervention: Combined sclerotherapy (short term followed by longterm)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Short term sclerotherapy only
Number of subjects: 106
Study: 3584738

Group type: EXPERIMENTAL
Intervention: Linoleic acid (23 g/d for 4 weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Oleic acid (23 g/d for 4 weeks)
Number of subjects: 17
Study: 29669883

Group type: EXPERIMENTAL
Intervention: Erythromycin (400 mg, twice daily for 48 weeks)
Number of subjects: 84
Study: 28854973

Group type: EXPERIMENTAL
Intervention: CCH 0.40 mg
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: CCH 0.60 mg
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: CCH 0.25 mg
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: CCH (all doses)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: CCH 0.40 mg and 0.60 mg
Number of subjects: 74
Study: 25456890

Group type: EXPERIMENTAL
Intervention: ToM training
Number of subjects: 72

Group type: COMPARATOR
Intervention: Physical‐conversation training
Number of subjects: 72

Group type: COMPARATOR
Intervention: Social-contact group
Number of subjects: 72
Study: 23977864

Group type: EXPERIMENTAL
Intervention: Exercise with blueberries (150 g on exercise days)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Exercise without blueberries (control)
Number of subjects: 26
Study: 21263103

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) program, 20 two-hour sessions over 1 year, median attendance 85%
Number of subjects: 362
Study: 18073232

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (n = 101)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Normal weight children (control group)
Number of subjects: 265
Study: 16864814

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 156

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 156
Study: 12755536

Group type: EXPERIMENTAL
Intervention: Simethicone-coated cellulose (SCC) 800 mL
Number of subjects: 40

Group type: COMPARATOR
Intervention: Water 800 mL
Number of subjects: 40
Study: 10690940

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/d
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 27
Study: 9124991

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (P/T)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (P/T) alone
Number of subjects: 15
Study: 7662242

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily, titrated to 100 mg if blood pressure uncontrolled after 6 weeks
Number of subjects: 202

Group type: COMPARATOR
Intervention: Atenolol 50 mg once daily, titrated to 100 mg if blood pressure uncontrolled after 6 weeks
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 202

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 202
Study: 2501722

Group type: EXPERIMENTAL
Intervention: K-Sol
Number of subjects: 99

Group type: COMPARATOR
Intervention: CSM (chondroitin sulfate corneal storage medium)
Number of subjects: 99

Group type: COMPARATOR
Intervention: CSM
Number of subjects: 99
Study: 267314

Group type: EXPERIMENTAL
Intervention: Apernyl
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 96
Study: 31929469

Group type: EXPERIMENTAL
Intervention: HIIT (High-Intensity Interval Training)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No-exercise control
Number of subjects: 50
Study: 28831250

Group type: EXPERIMENTAL
Intervention: Pulmonary Daoyin (PD) program, 3-month, ten times-weekly supervised rehabilitation
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Pulmonary Daoyin (PD) program
Number of subjects: 464

Group type: COMPARATOR
Intervention: Regular medical treatment (Control)
Number of subjects: 464
Study: 26856013

Group type: EXPERIMENTAL
Intervention: O'Nano toothbrush
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral-B Indicator 40 toothbrush
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison of both brushes
Number of subjects: 40
Study: 25112010

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (200 microg) in PCIA with fentanyl and tropisetron
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group without dexmedetomidine in PCIA
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (200 microg) in PCIA
Number of subjects: 91
Study: 21782353

Group type: EXPERIMENTAL
Intervention: Contingency participants (employment-based reinforcement)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Prescription participants (standard care)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups (Contingency and Prescription)
Number of subjects: 38
Study: 18972123

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with paclitaxel (200 mg/m²) and cisplatin (100 mg/m²)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by radiotherapy (69.9 Gy in 5.5 weeks)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by radiotherapy
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Number of subjects: 71
Study: 17140398

Group type: EXPERIMENTAL
Intervention: Isometric handgrip training (4 sessions of 2-min contractions at 30% of maximal effort, 3 times per week for 8 weeks)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Non-exercised arm (internal control)
Number of subjects: 11
Study: 16297751

Group type: EXPERIMENTAL
Intervention: Balanced inhalation anesthesia (BAL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Total intravenous anesthesia
Number of subjects: 50
Study: 11980997

Group type: EXPERIMENTAL
Intervention: Low-dose radiation therapy (50.4 Gy/28 fractions)
Number of subjects: 203

Group type: COMPARATOR
Intervention: High-dose radiation therapy (64.8 Gy/36 fractions)
Number of subjects: 203
Study: 9719019

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 8100

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 8100
Study: 8916993

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 4033
Study: 1663089

Group type: EXPERIMENTAL
Intervention: Oral itraconazole for a period of 6-8 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7078717

Group type: COMPARATOR
Intervention: Neutral, emotionally loaded, and 'mental task' stimuli; specific details on dosage and duration not available.
Number of subjects: 0
Study: 31641767

Group type: EXPERIMENTAL
Intervention: Oral antibiotics (ciprofloxacin)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Intravenous antibiotics (ceftriaxone)
Number of subjects: 152
Study: 30893483

Group type: EXPERIMENTAL
Intervention: Leaflet intervention
Number of subjects: 3003

Group type: EXPERIMENTAL
Intervention: Film intervention
Number of subjects: 3003

Group type: COMPARATOR
Intervention: No information
Number of subjects: 3003
Study: 28118256

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy plus amitriptyline (CBT+A)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Headache education plus amitriptyline (HE+A)
Number of subjects: 135
Study: 26051874

Group type: EXPERIMENTAL
Intervention: Empagliflozin 50 mg alone for 5 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Empagliflozin 10 mg coadministered with pioglitazone 45 mg for 7 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Empagliflozin 25 mg coadministered with pioglitazone 45 mg for 7 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Empagliflozin 50 mg coadministered with pioglitazone 45 mg for 7 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Empagliflozin and pioglitazone combination treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pioglitazone 45 mg alone for 7 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Empagliflozin 10 mg coadministered with pioglitazone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Empagliflozin 25 mg coadministered with pioglitazone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Empagliflozin 50 mg coadministered with pioglitazone
Number of subjects: 40
Study: 23538044

Group type: EXPERIMENTAL
Intervention: Transtibial technique
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Anteromedial portal technique
Number of subjects: 53
Study: 21735753

Group type: EXPERIMENTAL
Intervention: MK-0507A
Number of subjects: 474

Group type: COMPARATOR
Intervention: timolol
Number of subjects: 474

Group type: COMPARATOR
Intervention: concomitant therapy
Number of subjects: 474
Study: 19704072

Group type: EXPERIMENTAL
Intervention: Training category 1 (core trainer)
Number of subjects: 4994

Group type: EXPERIMENTAL
Intervention: Training category 2 (site trainer)
Number of subjects: 4994

Group type: EXPERIMENTAL
Intervention: Training category 3 (expedited group)
Number of subjects: 4994

Group type: EXPERIMENTAL
Intervention: All training methods combined
Number of subjects: 4994
Study: 16714852

Group type: EXPERIMENTAL
Intervention: Low-dose corticotropin stimulation test with 1 microg of 1-24 ACTH intravenously
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Decreasing daily equipotent doses of inhaled corticosteroids
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (40 age-matched controls)
Number of subjects: 100
Study: 15232700

Group type: EXPERIMENTAL
Intervention: 10-s feedback schedule
Number of subjects: 18

Group type: COMPARATOR
Intervention: 5-s feedback schedule
Number of subjects: 18

Group type: COMPARATOR
Intervention: 20-s feedback schedule
Number of subjects: 18
Study: 11310515

Group type: EXPERIMENTAL
Intervention: Triple combination tablet (abacavir 300 mg, lamivudine 150 mg, zidovudine 300 mg taken twice/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: ABC‐COM (abacavir 300 mg plus lamivudine 150 mg and zidovudine 300 mg taken twice/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Triple combination tablet
Number of subjects: 12

Group type: COMPARATOR
Intervention: ABC‐COM
Number of subjects: 12
Study: 1296419

Group type: EXPERIMENTAL
Intervention: Sodium metabisulphite
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 6540986

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dazoxiben
Number of subjects: 22
Study: 31139691

Group type: EXPERIMENTAL
Intervention: Nusinersen treatment
Number of subjects: 151

Group type: COMPARATOR
Intervention: Sham control treatment
Number of subjects: 151
Study: 29250762

Group type: EXPERIMENTAL
Intervention: 40-degree warm saline irrigation
Number of subjects: 150

Group type: COMPARATOR
Intervention: 20-25 degree saline irrigation (control)
Number of subjects: 150
Study: 27490921

Group type: EXPERIMENTAL
Intervention: Higher dose of hydrocortisone (0.4-0.6 mg/kg body weight)
Number of subjects: 47